Your Location：
Home >
Browse articles >
Are metformin-based combination approaches beneficial for non-small cell lung cancer: evidence from experimental and clinical studies
REVIEW | Updated：2026-03-26
Previous|Next

    • Are metformin-based combination approaches beneficial for non-small cell lung cancer: evidence from experimental and clinical studies

    • “A new study explores the potential of metformin, a common diabetes drug, in treating non-small cell lung cancer (NSCLC). Researchers reviewed extensive evidence on metformin’s anticancer effects and its synergistic potential with existing therapies. This research opens new avenues for improving NSCLC treatment outcomes.”
    • Anita Thyagarajan , Vaibhav Gajjar , Ravi P. Sahu
    • Military Medical Research Vol. 13, Issue 2, Pages: 267-283(2026)

    • DOI： 10.1186/s40779-025-00649-5     

      CLC：

    • Accepted：08 September 2025 ，

    Scan QR Code

  •  
  •  

  • AI Introduction

  • Full Text(HTML)

  • Figs( 2 ) Tabs( 3 )

  • References

  • Publication Info

  • Metrics

59

Views

33

Downloads

0

CSCD

Alert me when the article has been cited
Submit
Tools
  • BibTeXDownload
  • EndnoteDownload
  • RefMan Download
  • NoteExpressDownload
  • NoteFirstDownload

Related Articles

Bridging the lung cancer screening eligibility gap: evaluation of guideline applicability in asymptomatic patients
Reprogramming neural-tumor crosstalk: emerging therapeutic dimensions and targeting strategies
Impact of targeting the platelet-activating factor and its receptor in cancer treatment
Immune microenvironment dynamics in pregnant patients with concomitant autoimmune diseases: mechanisms, challenges, and clinical significance
Metabolic syndrome and risk of sepsis and sepsis-related mortality: evidence from two large prospective cohort studies

Related Author

Jie He
Chen-Ran Wang
Ren-Da Li
Pan Wang
Xue-Si Dong
Hao Zhang
Qing-Peng Zeng
Ni Li

Related Institution

Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Chinese Academy of Medical Sciences Key Laboratory for National Cancer Big Data Analysis and Implement, Chinese Academy of Medical Sciences and Peking Union Medical College
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Institute of Cancer Neuroscience, Medical Frontier Innovation Research Center, the First Hospital of Lanzhou University, the First Clinical Medical College of Lanzhou University